345 related articles for article (PubMed ID: 24026620)
41. Simple Enterographic Activity Score for Crohn's Disease: comparison with endoscopic, biochemical, and clinical findings.
Eder P; Katulska K; Lykowska-Szuber L; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
Pol Arch Med Wewn; 2013; 123(7-8):378-85. PubMed ID: 23778300
[TBL] [Abstract][Full Text] [Related]
42. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.
Kawashima K; Ishihara S; Yuki T; Fukuba N; Sonoyama H; Kazumori H; Yamashita N; Tada Y; Kusunoki R; Oka A; Oshima N; Mishima Y; Moriyama I; Kinoshita Y
Inflamm Bowel Dis; 2017 Nov; 23(11):2027-2034. PubMed ID: 28817462
[TBL] [Abstract][Full Text] [Related]
43. Correlation of 18F-FDG PET/MRE Metrics with Inflammatory Biomarkers in Patients with Crohn's Disease: A Pilot Study.
Domachevsky L; Leibovitzh H; Avni-Biron I; Lichtenstein L; Goldberg N; Nidam M; Groshar D; Bernstine H; Ben-Bassat O
Contrast Media Mol Imaging; 2017; 2017():7167292. PubMed ID: 29097934
[TBL] [Abstract][Full Text] [Related]
44. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
[TBL] [Abstract][Full Text] [Related]
45. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
[TBL] [Abstract][Full Text] [Related]
46. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index.
Koulaouzidis A; Douglas S; Plevris JN
Dig Dis Sci; 2012 Apr; 57(4):987-93. PubMed ID: 22057284
[TBL] [Abstract][Full Text] [Related]
47. Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy.
Klang E; Kopylov U; Eliakim R; Rozendorn N; Yablecovitch D; Lahat A; Ben-Horin S; Amitai MM
Clin Radiol; 2017 Sep; 72(9):798.e7-798.e13. PubMed ID: 28506799
[TBL] [Abstract][Full Text] [Related]
48. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
49. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
50. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
[TBL] [Abstract][Full Text] [Related]
51. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
Penna FGC; Rosa RM; Pereira FH; Cunha PFS; Sousa SCS; Ferrari TCA; Cara C; Ferrari MLA
Gastroenterol Hepatol; 2021 Feb; 44(2):87-95. PubMed ID: 32680729
[TBL] [Abstract][Full Text] [Related]
52. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy.
Iwamoto F; Matsuoka K; Motobayashi M; Takenaka K; Kuno T; Tanaka K; Tsukui Y; Kobayashi S; Yoshida T; Fujii T; Saito E; Yamaguchi T; Nagahori M; Sato T; Ohtsuka K; Enomoto N; Watanabe M
J Gastroenterol Hepatol; 2018 Dec; 33(12):1984-1989. PubMed ID: 29889986
[TBL] [Abstract][Full Text] [Related]
53. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
54. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease.
Garcia-Planella E; Mañosa M; Cabré E; Marín L; Gordillo J; Zabana Y; Boix J; Sáinz S; Domènech E
Inflamm Bowel Dis; 2016 Dec; 22(12):2879-2885. PubMed ID: 27824646
[TBL] [Abstract][Full Text] [Related]
55. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
56. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
57. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein.
Colombel JF; Solem CA; Sandborn WJ; Booya F; Loftus EV; Harmsen WS; Zinsmeister AR; Bodily KD; Fletcher JG
Gut; 2006 Nov; 55(11):1561-7. PubMed ID: 16648154
[TBL] [Abstract][Full Text] [Related]
58. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
59. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
[TBL] [Abstract][Full Text] [Related]
60. Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study.
Menys A; Atkinson D; Odille F; Ahmed A; Novelli M; Rodriguez-Justo M; Proctor I; Punwani S; Halligan S; Taylor SA
Eur Radiol; 2012 Nov; 22(11):2494-501. PubMed ID: 22661057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
